Plus d'informations
Scientists at the International Agency for Research on Cancer (IARC) have completed a study to assess the efficacy and safety of the use of therapeutic human papillomavirus (HPV) vaccines in phase II/III trials to treat women with moderate to advanced cervical lesions, and to achieve clearance of high-risk HPV from the cervix. The study was published in the journal BMJ Open.
Through a systematic review and meta-analysis, researchers in the Early Detection, Prevention, and Infections Branch at IARC determined that of 734 women with moderate to advanced cervical intraepithelial neoplasia (CIN) who received therapeutic HPV vaccines, 54% showed regression of their lesions. The proportion of HPV clearance in vaccinated women was 42%, which was more than double the clearance observed in unvaccinated women.
The study concluded that the vaccines had a modest efficacy in treating grade 2 or 3 lesions (CIN 2/3), and that the observed high HPV clearance rates should be studied further to determine whether therapeutic HPV vaccination may lead to a more rapid and durable elimination of the virus in HPV-positive women with no precancerous or cancerous lesions.
The World Health Organization (WHO) is currently developing product performance characteristics (PPCs) for therapeutic HPV vaccines, through a consultative and iterative process with global partners including the Bill & Melinda Gates Foundation. This systematic review will provide valuable evidence to this WHO initiative, which aims to add a novel strategy for cervical cancer elimination to the existing ones.
Ibrahim Khalil A, Zhang L, Muwonge R, Sauvaget C, Basu P.
